Navigation Links
Studies show Vectra(TM) DA can track early response to rheumatoid arthritis therapy
Date:5/24/2011

LONDON (May 25, 2011) Crescendo Bioscience today announced data indicating that Vectra DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis (RA) disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy. Additional studies show that the score from the Vectra DA algorithm has the potential to predict progressive joint damage and is robust in RA patients who have common comorbid conditions. Two additional studies confirmed Vectra DA algorithm's ability to quantify RA disease activity including the ability to discriminate between low disease activity and remission. These data were presented at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology in London, May 25 28, 2011. Additional studies of pipeline products were also presented, including work to develop a multi-biomarker test for risk of structural damage in RA.

"These data indicate that Vectra DA can provide physicians with a robust molecular monitoring system for RA disease activity," said Stephen Paget, M.D., Physician-in-Chief Emeritus, Hospital for Special Surgery. "Vectra DA may help physicians determine whether a patient is responding to therapy, perhaps as early as two weeks after initiating treatment, and whether additional intervention may be necessary."

RA is a debilitating, highly variable, chronic disease that often results in joint damage and disability. Vectra DA is the first multi-biomarker blood test to assess RA disease activity, integrating information from 12 key biomarkers with a proven association with RA disease activity into a single quantitative score.

"The underlying biology of RA can vary greatly among patients and often changes over time," said David Chernoff, MD, Chief Medical Officer of Crescendo Bioscience. "These data further validate Vectra DA's broad utility in providing physicians with quantitative information on RA disease activity and underlying biology. Vectra DA provides a tool to help personalize patient management."

Overview of Vectra DA Algorithm Data

Use of a Multi-Biomarker Score for Rheumatoid Arthritis Disease Activity (Vectra DA) to Assess Response to Therapy (Poster Session I: May 26, 2011, 11:45 BST)

Patients from the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) diagnosed with RA received methotrexate (MTX) or anti-TNF therapy with MTX, based on their physician's recommendation. Changes in the Vectra DA algorithm score occurred as early as two weeks after initiating therapy and were significantly associated with subsequent clinical responses (p=0.01).

A Multi-Biomarker Algorithm for RA Disease Activity (Vectra DA) Predicts Radiographic Progression in the BeSt Study (Poster Session I: May 26, 201, 11:45 BST)

Researchers analyzed blood samples from baseline and year one of 124 patients from the Behandel Strategieen (BeSt) clinical study to determine whether, in addition to its validated use to assess and track disease activity, the Vectra DA algorithm could help predict progressive joint damage. Disease activity is a significant risk factor for joint damage.

The Vectra DA algorithm score was significantly associated with joint damage progression, (p< 0.001). In a multivariate regression analysis including other disease activity measurements, only the Vectra DA algorithm score was a significant predictor of the second year change in Van der Heijde Sharp Score, a common radiographic scoring method used to assess joint damage in RA (p< 0.05). The results suggest that the combination of biomarkers in the Vectra DA algorithm reflects the underlying disease processes.

Robustness of a Novel Multi-Biomarker Score for RA Disease Activity (Vectra DA) Across a Spectrum of Co-Morbidities and Smoking Status (Poster Session II: May 27, 2011, 11:45 BST)

This study selected 512 subjects from the InFoRM Study, a geographically diverse North American cohort, and assessed whether comorbid conditions affected disease activity measures. The study found that common comorbid conditions had no significant impact on the Vectra DA algorithm score. In an exploratory analysis of patients with fibromyalgia, the Vectra DA algorithm score had greater observed stability than the other common disease activity measures DAS28, CDAI and CRP.

A Multi-Biomarker Based Disease Activity (MBDA) Score System Compared to a Conventional Disease Activity Score (DAS) System in the BeSt Rheumatoid Arthritis (RA) Study (Poster Session III: May 28, 2011, 10:15 BST)

Blood samples were analyzed from 124 RA patients at 180 visits in the BeSt study. The Vectra DA algorithm score was significantly correlated with three standard clinical disease activity scores (DAS, DAS28 and DAS28CRP; p< 0.001 in all cases). In addition, change in the Vectra DA algorithm score was significantly correlated with change in DAS28 between baseline and 1 year study visits, indicating that the Vectra DA algorithm can track changes in disease activity over time.

Biomarker Signatures in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study (Poster Session III: May 28, 2011, 10:15 BST)

Blood samples from the UK based REMIRA (Remission in RA) study acquired at baseline from 70 RA patients on stable therapy with less than 10 years of disease and DAS28 of less than 3.2 were examined to determine whether Vectra DA could differentiate between low disease activity and remission. Multiple definitions of remission were assessed, including those for standard clinical disease activity scores (DAS28, CDAI, SDAI) and the new American College of Rheumatology (ACR)/EULAR criteria.

A statistically significant (p< 0.01 in all cases) association was observed between the Vectra DA algorithm score and the current clinical standards for evaluating RA remission vs. non-remission.

Overview of Multi-Biomarker Structural Damage Test Data

Development of A Multi-Biomarker Algorithm to Predict RA Structural Damage in the Leiden Early Arthritis Cohort (Poster Session II: May 27, 2011, 11:45 BST)

Researchers evaluated both individual biomarkers and prototype multi-biomarker models to predict the risk and degree of joint damage in an individual patient over 12 months. Biomarker concentrations were determined in 307 blood samples from 187 patients in the Leiden Early Arthritis Cohort, a Dutch population-based cohort.

The study found that biomarker combinations had higher observed performance than conventional clinical measures at predicting progressive structural damage in RA. A multi-biomarker test, if validated, has the potential to better predict structural damage in clinical practice.


'/>"/>

Contact: June Fujimoto
jfujimoto@crescendobio.com
650-351-3065
GCI Health
Source:Eurekalert

Related medicine news :

1. UC studies show marijuana has therapeutic value, reports to legislature
2. Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies
3. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
4. COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology
5. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
6. Most Drug Studies Dont Help Docs Pick Best Treatment
7. Gays, Lesbians Excluded From Some Medical Studies
8. Studies Show Significant Increases of C. Difficile Infections (CDI)
9. Studies examine Third Eye Retroscope during colonoscopy
10. Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation
11. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: